J Invest Dermatol 2021 Jun 2. Epub 2021 Jun 2.
Institute for Cancer Genetics, Columbia University, New York, NY, USA; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. Electronic address:
Sézary Syndrome (SS) is an aggressive and disseminated form of Cutaneous T-cell lymphoma (CTCL) associated with dismal prognosis in which the histone deacetylase inhibitor romidepsin, has shown remarkable activity as a single agent. However, clinical responses to romidepsin are typically transient, highlighting the need for more effective therapies. Here, we show synergistic anti-lymphoma effects of romidepsin in combination with mechlorethamine, an alkylating agent, in CTCL cell lines and primary samples with strong antitumor effects in an in vivo model of SS. Read More